Why the study?
Does the platelet-function analyzer (PFA-100) provide a useful screening tool for evaluating primary hemostasis compared to in vivo bleeding time?
Does the platelet-function analyzer (PFA-100) provide a useful screening tool for evaluating primary hemostasis compared to in vivo bleeding time?
The PFA-100 is a rapid and sensitive in vitro device that could replace the traditional in vivo bleeding time test for screening primary hemostasis disorders.
Answers are grounded in this paper and cite their sources.
May support PFA-100 for primary hemostasis screening; leaves open prospective validation before replacing bleeding time.
The platelet-function analyzer, PFA-100, is a relatively novel method for rapid in vitro global evaluation of primary hemostasis. The aim of this review is to summarize the published studies reporting on the utility of the PFA-100 device as a screening tool for primary hemostasis. Data were identified by searches of the published literature, including PubMed, references from reviews and abstracts from the most important meetings on this topic. The literature data support the use of the PFA-100 as a useful screening tool for the investigation of von Willebrand's disease and other acquired and congenital intrinsic platelet function disorders. Moreover, it is useful for evaluating primary hemostasis before surgical procedures and for monitoring desmopressin therapy in both von Willebrand's disease and platelet function disorders. Given its high sensitivity, speed and simplicity of use, we conclude that the PFA-100 could replace the in vivo bleeding time as a screening test for primary hemostasis in routine clinical practice.
No takes yet. Share an insight, caveat, or question.
Massimo Franchini (2005) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: